Research programme: SARS-CoV-2 papain like protease inhibitors - Clear Creek Bio/Pfizer
Alternative Names: SARS-CoV-2 PLpro inhibitors - Clear Creek Bio/PfizerLatest Information Update: 30 Dec 2022
At a glance
- Originator Clear Creek Bio; Pfizer
- Developer Clear Creek Bio
- Class Antivirals; Small molecules
- Mechanism of Action SARS-CoV-2 papain-like protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections